You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中国抗体-B(03681.HK)上市翌日股价续挫12% 华领(02552.HK)再挫19%
阿思达克 11-13 12:01

仍未有任何盈利中国抗体-B(03681.HK)继首挂日股价低收挫21%後,今早进一步跌至5.22元才喘定,半日收5.27元,续挫12%,成交1,603万股,涉资8,669万元。中国抗体是专门研发、制造及商业化免疫性疾病疗法的香港生物制药公司。是次以每股7.6元上市净筹12.86亿元,主要用作研发和商业化其核心产品及建设苏州生产基地等。

另一只仍未录得盈利去年9月才以每股8.28元上市的华领医药(02552.HK)继昨天指无法保证治疗糖尿病新药dorzagliatin(HMS5552)明年次季可成功开发导致股价倒跌16%後,今天进一步下挫,最多再挫28%低见4.1元再创上市新低,半日收4.64元,续挫19%,成交284万股。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account